Dupilumab in Japanese patients with atopic dermatitis

Trial Identifier: EFC16823
Sponsor: Sanofi
Collaborator:
Regeneron
Start Date: January 2021
Primary Completion Date: December 2021
Study Completion Date: October 2023
Condition: Eczema

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
JAPAN, Aichi Nagoya-shi, Aichi, JAPAN, 457-8510
JAPAN, Aichi Toyoake-shi, Aichi, JAPAN, 470-1192
JAPAN, Fukuoka Fukutsu-shi, Fukuoka, JAPAN, 811-3217
JAPAN, Hiroshima Hiroshima-shi, Hiroshima, JAPAN, 734-8551
JAPAN, Hokkaido Sapporo-shi, Hokkaido, JAPAN, 060-0807
JAPAN, Hokkaido Sapporo-shi, Hokkaido, JAPAN, 004-0063
JAPAN, Hyogo Kobe-shi, Hyogo, JAPAN, 658-0082
JAPAN, Hyogo Kobe-shi, Hyogo, JAPAN, 653-0836
JAPAN, Kanagawa Sagamihara-shi, Kanagawa, JAPAN, 252-0392
JAPAN, Kanagawa Yokohama-shi, Kanagawa, JAPAN, 225-0015
JAPAN, Kanagawa Yokohama-Shi, Kanagawa, JAPAN, 221-0825
JAPAN, Mie Tsu-shi, Mie, JAPAN, 514-0125
JAPAN, Not Known Habikino-shi, Not Known, JAPAN, 583-8588
JAPAN, Osaka Sakai-shi, Osaka, JAPAN, 593-8324
JAPAN, Osaka Toyonaka-shi, Osaka, JAPAN, 560-0085
JAPAN, Saitama Kumagaya-shi, Saitama, JAPAN, 360-0018
JAPAN, Tokyo Chuo-ku, Tokyo, JAPAN, 104-0031
JAPAN, Tokyo Koto-ku, Tokyo, JAPAN, 136-0074
JAPAN, Tokyo Toshima-ku, Tokyo, JAPAN, 170-0002